Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Lisocabtagene Maraleucel: A Review of TRANSCEND NHL 001 in R/R LBCL

December 19th 2023

Gain insights into treatment outcomes of CAR T, highlighting lisocabtagene maraleucel and the TRANSCEND NHL 001 study for R/R LBCL.

Current Treatment Options in First-line FL

December 18th 2023

Experts on follicular lymphoma discuss first-line treatment options available for patients.

Role of Allogeneic Transplants in Hematologic Malignancies

December 15th 2023

Experts discuss what role allogeneic transplants play in hematologic malignancies, specifically in AML and ALL.

AML Update: Incidence, Risk Factors, and Prognosis

December 15th 2023

Join Catherine Lai, MD, MPH in this informative OncLive News Network program as she explores strategies for optimizing outcomes in the long-term management of Acute Myeloid Leukemia (AML), with a focus on patients in first remission without a transplant. Here, she provides a brief overview of the current incidence of AML, its risk factors, and prognosis.

Dr Jain on the Importance of Novel Therapies in Pediatric Patients With Bleeding Disorders

December 15th 2023

Akshat Jain, MBBS, discusses the importance of novel therapies in the treatment of pediatric patients with beleeding disorders.

Taking Trial Data to the Clinic in MPN and CLL From ASH 2023: Drs Rogers, Brown, and Shammo

December 13th 2023

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASH Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Asciminib Elicits Safe and Durable Responses in Previously Treated CML

December 12th 2023

Treatment with asciminib elicited greater efficacy and had a more tolerable safety profile compared with bosutinib for patients chronic myeloid leukemia in chronic phase following treatment with 2 or more TKIs.

Acimtamig Plus Allogeneic Natural Killer Cells Under Phase 2 Evaluation in R/R Hodgkin Lymphoma and CD30+ PTCL

December 12th 2023

Following promising preclincial findings, acimtamig plus allogenic natural killer cells will be examined for the treatment of patients with relapsed/refractory Hodgkin lymphoma and CD30-positive peripheral T-cell lymphoma.

Axi-Cel Provides Sustained Response in High-Risk Large B-cell Lymphoma

December 12th 2023

Patients with high-risk large B-cell lymphoma experienced durable responses when treated with first-line axicabtagene ciloleucel, according to results from the phase 2 ZUMA-12 trial.

Tafasitamab Quadruplet Shows Efficacy in Newly Diagnosed DLBCL

December 12th 2023

The use of tafasitamab-cxix, lenalidomide, rituximab, and acalabrutinib in the first-line setting induced high responses in patients with newly diagnosed diffuse large B-cell lymphoma, with responders deriving benefit from subsequent treatment with cyclophosphamide, doxorubicin, vincristine, and prednisolone.

Pirtobrutinib Displays Activity in Relapsed/Refractory MCL Following Covalent BTK Inhibitor Therapy

December 12th 2023

Pirtobrutinib demonstrated promising efficacy and a tolerable safety profile in heavily pretreated patients with relapsed/refractory mantle cell lymphoma who received prior therapy with a covalent BTK inhibitor.

BGB-16673 Delivers Responses With a Tolerable Safety Profile Across R/R B-Cell Malignancies

December 12th 2023

The novel BTK degrader BGB-16673 was well tolerated; produced meaningful and rapid clinical responses; and demonstrated on-target effects in patients with relapsed/refractory B-cell malignancies.

Revumenib Elicits High Response Rate in R/R KMT2A-Rearranged Acute Leukemia

December 12th 2023

Revumenib demonstrated clinically meaningful activity, including high response and minimal residual disease negativity rates, in heavily pretreated patients with KMT2A-rearranged acute leukemia.

NX-2127 Elicits Responses With Manageable Safety in Heavily Pretreated B-cell Malignancies

December 12th 2023

NX-2127 showcased early efficacy in the form of responses with an acceptable toxicity profile in patients with relapsed or refractory B-cell malignancies, according to data from the ongoing phase 1 NX-2127-001 trial.

Looking at the Latest Data in Multiple Myeloma and Lymphoma From ASH 2023: Drs Landgren and Saeed

December 12th 2023

ZUMA-1: Axi-Cel in Relapsed/Refractory LBCL

December 12th 2023

A dive into the latest results from the ZUMA-1 study, evaluating axicabtagene ciloleucel (axi-cel) in relapsed/refractory LBCL.

Approaches to Treatment Sequencing in LBCL

December 12th 2023

Expert perspective on treatment sequencing strategies for patients with LBCL.

Innovations in Immunotherapy: CAR T-Cells, Allogeneic Approaches, and Bispecifics

December 12th 2023

Expert perspective on advancements in cancer immunotherapy, including CAR-T cells, allogeneic strategies, and the role of bispecific antibodies.

Orca-Q Showcases Early Efficacy, Acceptable Safety in Haploidentical Stem Cell Transplant Without PTCy

December 12th 2023

The high-precision cellular product Orca-Q demonstrated early signals of clinical activity as well as an acceptable safety profile for patients undergoing haploidentical stem cell transplantation without posttransplant cyclophosphamide.

Zanubrutinib May Be Viable Option After Acalabrutinib Intolerance in B-Cell Malignancies

December 11th 2023

Patients with B-cell malignancies who were intolerant to treatment with acalabrutinib experienced clinically meaningful benefits when treated with zanubrutinib, suggesting zanubrutinib may be a viable treatment option for this population.